Palatin Technologies, Inc. announced today that data from two pivotal,
double-blind placebo-controlled Phase 3 trials (RECONNECT) and the Exit Survey/Interview data
on Vyleesi\u2122 (bremelanotide injection) for hypoactive sexual desire disorder (HSDD)
will be presented at the 13th European Society of Gynecology Conference in Vienna, Austria.
quelle https://finance.yahoo.com/news/vyleesi-phase-3-data-presente…
zum poster :
Bremelanotide Provides Meaningful Treatment Benefits for
Premenopausal Women With Hypoactive Sexual Desire Disorder
https://www.palatin.com//assets/Treatment-Benefits-Poster.pd…